Copper is an essential metal ion for embryonic development, iron acquisition, cardiac function, neuropeptide biogenesis, and other critical physiological processes. Ctr1 is a high affinity Cu⁺ transporter on the plasma membrane and endosomes that exists as a full-length protein and a truncated form of Ctr1 lacking the methionine- and histidine-rich metal-binding ectodomain, and it exhibits reduced Cu⁺ transport activity. Here, we identify the cathepsin L/B endolysosomal proteases functioning in a direct and rate-limiting step in the Ctr1 ectodomain cleavage. Cells and mice lacking cathepsin L accumulate full-length Ctr1 and hyper-accumulate copper. As Ctr1 also transports the chemotherapeutic drug cisplatin via direct binding to the ectodomain, we demonstrate that the combination of cisplatin with a cathepsin L/B inhibitor enhances cisplatin uptake and cell killing. These studies identify a new processing event and the key protease that cleaves the Ctr1 metal-binding ectodomain, which functions to regulate cellular Cu⁺ and cisplatin accumulation.

Copper is essential for key biological processes, including electron transfer, iron acquisition, dopamine hydrolysis, and superoxide disproportionation, and defects in copper metabolism are associated with cardiomyopathy, anemia, peripheral neuropathy, and neutropenia (1–6). Although many proteins involved in the acquisition and intracellular distribution of copper have been identified, little is known about the regulation of copper import. The transport of Cu⁺ from the extracellular environment is accomplished by the evolutionarily conserved homotrimeric integral membrane protein, copper transporter 1 (Ctr1) (7–13), which resides on the plasma membrane and in endosomal compartments (14–18). High affinity Cu⁺ import via Ctr1 requires a methionine- and histidine-rich metal-binding extracellular domain (ectodomain) that is thought to concentrate extracellular Cu⁺ near the ion trans-membrane pore (19–23). Additionally, Ctr1 binds the chemotherapeutic agent cisplatin via the methionine ligands in the ectodomain and imports cisplatin and other platinum-based chemotherapeutic agents via an endocytic mechanism (24–28). Despite a critical role for the Ctr1 ectodomain in both Cu⁺ and cisplatin import, both a full-length form and a truncated form of Ctr1 (tCtr1) are present in cultured cells and tissues (18, 29, 30). The latter lacks the ectodomain and drives ~50% of the Cu⁺ uptake as compared with full-length Ctr1 (31).

Previously, an integral membrane protein similar to Ctr1, denoted Ctr2, was shown to both interact with and regulate the ratio of full-length Ctr1 to tCtr1 in mouse embryonic fibroblasts (MEFs) and in specific tissues in Ctr2 knock-out mice (32). In the absence of Ctr2, MEFs possess dramatically lower levels of tCtr1, while simultaneously expressing high levels of full-length Ctr1 and accumulating Cu⁺ and cisplatin. A large fraction of the Cu⁺ accumulated in Ctr2⁻/⁻ MEFs and mouse tissues is found in endosomal compartments (32). The mechanism by which Ctr2 governs the abundance of tCtr1, thereby controlling Cu⁺ and cisplatin accumulation, and the subcellular location in which this process occurs have not been elucidated.

Here, we report that Ctr2 stimulates the proteolytic processing of full-length Ctr1 to yield tCtr1 and that this process is due to direct Ctr1 ectodomain cleavage by the endolysosomal cysteine proteases, cathepsins L and B. Both proteases co-purify with endolysosomes harboring Ctr1 and Ctr2, consistent with
Processing of Ctr1 Ectodomain
ectodomain processing occurring in the acidic endolysosomal compartment. Pharmacological or genetic inhibition of cathepsins L and B results in the accumulation of full-length Ctr1 and drives increased copper accumulation both in MEFs and in cathepsin knock-out mice. Similarly, treatment of cells with cisplatin, in combination with a cathepsin L/B inhibitor, enhances cisplatin accumulation and sensitizes cells to cisplatin toxicity. These findings identify a regulatory mechanism for modulating Ctr1-mediated Cu\(^{2+}\) and cisplatin uptake and identify the cathepsin L and B prostates as new components of the metal homeostasis machinery that are amenable to pharmacological manipulation.

Experimental Procedures

Chemicals—Protease inhibitors, including TIMP-2 and -3 (R&D Systems), TAPI-2, cathepsin L inhibitor III (benzoyloxycarbonyl FY(t-Bu)-DMK) (Calbiochem, EMD), BB-94 (Bati-mastat, Tocris Biosciences), E64d ((2S,3S)-trans-epoxy-succinyl-\(-\)leucylamido-3-methylbutane ethyl ester), and CA074Me (Sigma), were purchased from the indicated vendors.

Animals and Ethical Statement—Wild type (WT) and cathepsin L\(^{-/-}\) mice were euthanized by CO\(_2\) and perfused with PBS, and the selected tissues were dissected, snap-frozen in liquid nitrogen, and stored at \(-80^\circ\)C until use. All procedures were approved by the Ethical Committee at the Albert-Ludwigs-Universität in Freiburg, Germany.

Cell Culture, Generation of Cell Lines, and Transfections—Wild type and cathepsin L\(^{-/-}\), cathepsin B\(^{-/-}\), and cathepsin L\(^{-/-}\); B\(^{-/-}\) MEFs were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 1\(\times\) MEM non-essential amino acids, and 1\(\times\) antibiotic/antimycotic. Wild type (Ctrl2\(^{+/+}\)), Ctrl2\(^{-/-}\), and doxycycline-inducible Ctrl2\(^{-/-}\) MEFs were cultured in DMEM supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 1\(\times\) MEM non-essential amino acids, 2\(\times\) MEM HEPES, 1\(\times\) antibiotic/antimycotic, 55 \(\mu\)M \(\beta\)-mercaptoethanol, and 100 \(\mu\)g/ml hygromycin B. Wild type, Ctrl1\(^{-/-}\), and Ctrl1\(^{-/-}\); Ctrl2\(^{-/-}\) MEFs and derivatives harboring a Tet-On-Ctrl2 allele, were cultured in DMEM (Gibco) supplemented with 20% (v/v) heat-inactivated FBS, 1\(\times\) MEM non-essential amino acids, 50 \(\mu\)g/ml uridine, 100 units/ml penicillin/streptomycin, and 55 \(\mu\)M \(\beta\)-mercaptoethanol. HEK293T cells were cultured in DMEM supplemented with 10% (v/v) heat-inactivated fetal bovine serum and 100 units/ml penicillin/streptomycin. Chinese hamster ovary (CHO) cells were cultured in F-12K medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum. A doxycycline-regulated Ctrl2 cell line was generated using the pTRIPZ vector (GE Healthcare). Briefly, the RFP gene in this plasmid was replaced with a mouse Ctrl2 cDNA by standard cloning methods. Lentiviral particles were used to infect Ctrl2\(^{-/-}\) and stable clones selected via puromycin treatment and purified. MEFs lacking both Ctrl1 and Ctrl2 were generated by transfecting Ctrl1\(^{-/-}\) MEFs with a plasmid expressing Cas9 and a guide RNA specific for Ctrl2. Clones were screened via PCR and a single clone lacking an intact Ctrl2 reading frame was selected and cultured under 3% CO\(_2\) at 37°C. For cell viability assays Ctrl1\(^{+/+}\) and Ctrl1\(^{-/-}\) MEFs were seeded at a density of 20,000 cells/well in a transparent 96-well plate. Cells were pre-treated with E64d for 2 h before 50 \(\mu\)M cisplatin was added, and cells were incubated for 12 h. CellTiter Blue (Promega) was used to measure cell viability according to the instructions of the manufacturer, analyzing the metabolic capacity in living cells by recording the reduction of the dye resazurin into the fluorescent end product resorufin at 560\(_{\text{Em}}\)/590\(_{\text{Em}}\) nm.

Transfection into MEFs was carried out by electroporation using Amaxa Nucleofection MEF2 kit (Lonza) according to the manufacturer’s instructions. The vector pcDNA3.1(+) backbone was used when transfecting human CTRL1 into Ctrl1\(^{-/-}\) MEFs. The SMARTpool siRNA for mouse Ctrl2 (SLC31A2) (Dharmacon) was used to knock down Ctrl2 expression in cathepsin L\(^{-/-}\) MEFs. MEFs were seeded in 6-well plates at a density of 1 \times 10^6 cells/well. The following day siRNA or scRNA (non-targeting RNA) were added and incubated for 72 h before collection for analysis.

Protein Extraction and Immunoblotting—For the isolation of protein extracts, mouse tissues or cell pellets were homogenized in \(-10\) volumes of ice-cold lysis buffer (phosphate-buffered saline (PBS, pH 7.4), 1% Triton X-100, 0.1% SDS, and 1 mM EDTA, protease inhibitors (Halt Protease Inhibitor Mixture, Thermo Scientific)); homogenates were incubated in ice for 30 min and centrifuged at 16,000 \(\times\)g at 4°C for 20 min, and supernatants were collected. Protein concentrations were measured with the BCA protein assay kit (Thermo Scientific). SDS-PAGE and immunoblotting were carried out by standard protocols. Anti-Ctrl1 and anti-Ctrl2 antibodies have been described previously. Antibodies used were anti-cytochrome c oxidase (CoxIV; Mitosciences, Eugene, OR), anti-cathepsin L (Santa Cruz Biotechnology, Santa Cruz, CA), anti-cathepsin B and anti-glycer-aldehyde-3-phosphate dehydrogenase (GAPDH) (Abcam), anti-\(\beta\)-tubulin and anti-Lamp1 (Cell Signaling Technology, Danvers, MA), and anti-Cu/Zn superoxide dismutase (SOD1; StressGen, Ann Arbor, MI). Horseradish peroxidase (HRP)-conjugated anti-mouse or -rabbit IgG (GE Healthcare) were used as secondary antibody for immunoblotting.

Tissue and Cell Metal Measurements—Tissue and whole cell copper and zinc concentrations were measured by ICP-MS. Briefly, tissues were collected into acid-washed 1.5-ml micro-centrifuge tubes and weighed. The cultured cells were rinsed once with PBS, harvested into ice-cold PBS, and divided into two tubes. One tube was used to measure protein content, and the other sample was collected by centrifugation at 400 \(\times\)g for 5 min at 4°C. Tissues or cell pellets were suspended in 10 times volume/weight (\(\mu\)l/mg wet weight) of trace analysis grade nitric acid (Sigma), heated at 85–95°C for \(-1\) h, and subjected to ICP-MS analysis. For cisplatin accumulation, Ctrl1\(^{-/-}\) cells were transfected with either empty vector or human Ctrl1 and pretreated with DMSO or 10 \(\mu\)M cathepsin L inhibitor prior to treatment with 200 \(\mu\)M cisplatin (American Pharmaceutical Partners, Inc., Los Angeles) in Opti-MEM for 2 h and digested in HNO\(_3\)/HCl (3:1) followed by ICP-MS. The analyses were performed by Environmental and Agricultural Testing Service, Department of Soil Science, North Carolina State University, Raleigh. Values were normalized by protein concentration or tissue wet weight.
**Processing of Ctr1 Ectodomain**

Discontinuous Density Gradient Fractionation—Ctr2+/+,
Ctr2−/−, and WT MEFs were cultured in 15-cm diameter
dishes until confluent, rinsed twice with ice-cold PBS, scraped,
and pelleted at 900 × g for 2 min at 4 °C. The 200−250-mg (wet
weight) pellets were dissolved by gentle vortexing in 800 μl
of lysis buffer with protease inhibitors, incubated in ice for 2 min,
and subjected to sonication with 10 bursts in ice with a pre-
cooled probe. Lysates were centrifuged at 500 × g for 10 min
4 °C to pellet the nuclear fraction, and supernatants were frac-
tionated by discontinuous iodixanol density gradient centrifu-
gation (Thermo Scientific) at 145,000 × g for 2 h at 4 °C in a
swing rotor. Three fractions were collected, and each fraction
was divided into 3 aliquots for protein quantitation, ICP-MS
analysis, and immunoblotting.

Ctr1 Ectodomain Purification and Cleavage—Recombinant
human CTR1 ectodomain (residues 1−55) was expressed as an
amino-terminal SUMO fusion followed by a FLAG tag, CTR1
ectodomain, and a carboxyl-terminal Strep II tag. This coding
region was subcloned into the pET-15b vector, transformed
into Escherichia coli BL21 (DE3) cells, and expressed at 37 °C
for ~4 h with 1 mM isopropyl β-D-galactopyranoside. Cells
were lysed via sonication in 100 mM Tris, 150 mM NaCl, 1
mM EDTA and centrifuged to remove debris, and the lysate was
loaded onto a 5-ml StrepTrap FPLC column (GE Healthcare),
washed with lysis buffer, and eluted with lysis buffer supple-
mented with 5 mM d-desthiobiotin. Fractions containing the
CTR1 ectodomain were pooled and treated with SUMO prote-
ase (Invitrogen), and the ectodomain was separated from the
SUMO moiety by size fractionation over a Superdex 75 26/60
FPLC column (GE Healthcare). Fractions were pooled and con-
centrated to 40 μM. Purified recombinant cathepsin L prepared
as described (33) was activated by a 30-min incubation in Acti-
vation Buffer (25 mM NaOAc, pH 5.5, 150 mM NaCl, 1 mM
EDTA, 2 mM DTT), diluted to appropriate concentrations in
Reaction Buffer (100 mM MES, pH 6.0, 150 mM NaCl, 1 mM
EDTA), and mixed in a 1:1 (v/v) ratio with recombinant CTR1
ectodomain. Reactions were incubated at 37 °C for 1 h, termi-
nated with the addition of SDS-PAGE loading buffer, and
resolved by SDS-PAGE. Samples subjected to peptide analysis
were treated as above with reactions terminated by a 5-min
incubation at 95 °C prior to analysis by LC-MS/MS performed
by the Duke University Proteomics Core.

**Results**

Ctr2 Stimulates Ctr1 Ectodomain Cleavage by Cysteine
Proteases—in mouse and human cells Ctr1 and tCtr1 differ by
the presence or absence of a histidine- and methionine-rich
glycosylated ectodomain, in which tCtr1 initiates at a small
cluster of sites previously identified by mass spectrometry (Fig.
1A) (32). Ctr2 forms a complex with Ctr1 in vivo and positively
influences the abundance of the tCtr1 species. To ascertain the
role of Ctr2 in regulating the biogenesis of tCtr1, the temporal
effect of Ctr2 expression on the appearance of the two Ctr1
species was investigated in a Ctr2−/− MEF line in which Ctr2
expression is controlled by doxycycline. As shown in Fig. 1B,
Ctr2 expression was paralleled by a time-dependent increase in
the appearance of tCtr1. Notably, the formation of tCtr1 was
accompanied by a corresponding reduction in the full-length
Ctr1, suggesting that the formation of the tCtr1 may be due to
proteolytic processing of full-length Ctr1, rather than stabiliza-
tion of the tCtr1 protein by Ctr2. Although this precursor-
product relationship between full-length and tCtr1 is often
observed, in some experiments the reduction in tCtr1 is not
accompanied by an increase in full-length Ctr1 and could
reflect differences in stability. To determine the nature of this
putative proteolytic process involved in tCtr1 generation, a col-
lection of protease inhibitors was evaluated for their effect on
the abundance of the tCtr1 species in wild type (WT) MEFs. A
broad range of protease inhibitors was tested, including the
matrix metalloprotease inhibitors TIMP-2, TIMP-3, BB-94
(Batimastat), and the ADAM17, -15, -8, -10, and -12 inhibitor
TAPI-2. However, none of these or other inhibitors influenced
the abundance of tCtr1 (Fig. 1C). In contrast, MEFs treated with
the cysteine cathepsin/calpain protease inhibitor E64d dis-
played a striking reduction in the levels of tCtr1, suggesting that
one or more E64d-inhibitable proteases are involved in the pro-
teolytic processing of the Ctr1 ectodomain (Fig. 1D). A reduc-
tion in tCtr1 levels is also observed when Chinese hamster
ovary cells (CHO) or human embryonic kidney cells (HEK293T)
were treated with E64d, suggesting that Ctr1 truncation
occurs via a proteolytic mechanism that is conserved
among these species. The robust increase in tCtr1 levels caused
by induced expression of Ctr2 can be abrogated by incubation
with E64d (Fig. 1E). Together, these results suggest that the
generation of tCtr1 is a conserved proteolytic process mediated
by an E64d-inhibitable protease activity that acts downstream
of Ctr2.

Cathepsin Inhibition Decreases tCtr1 Levels and Increases
Copper Accumulation—The cell-permeable and irreversible
protease inhibitor E64d inhibits cysteine cathepsin proteases,
with a preference for cathepsins L and B at the doses used in our
experiments, as well as the calcium-dependent calpain prote-
ases (34). To explore which of these protease families is rele-
ant for the formation of tCtr1, proteases were evaluated for
co-localization with Ctr1 and Ctr2. Ctr1 has been shown to
continuously cycle between the plasma membrane and endo-
cytic vesicles, where it localizes to endolysosomal compart-
ments that also harbor Ctr2 (14, 30, 32, 35). Because Ctr1 clea-
amage has previously been suggested to occur at an endosomal
compartment (30), subcellular fractionation was carried out in
an attempt to localize Ctr1 with the appropriate protease. The
Ctr1 ectodomain faces the intraluminal space, and thus any
protease involved in Ctr1 cleavage must be present inside the
vesicular lumen. Because calpain proteases are localized to the
cytosol, our studies focused on cathepsins L and B as they are
known to primarily localize to endolysosomal compart-
ments. Analysis of subcellular fractions by immunoblotting revealed
that Ctr1, Ctr2, and cathepsins L and B co-fractionated
putative proteolytic process involved in tCtr1 generation, a col-
lection of protease inhibitors was evaluated for their effect on
the abundance of the tCtr1 species in wild type (WT) MEFs. A
broad range of protease inhibitors was tested, including the
matrix metalloprotease inhibitors TIMP-2, TIMP-3, BB-94
(Batimastat), and the ADAM17, -15, -8, -10, and -12 inhibitor
TAPI-2. However, none of these or other inhibitors influenced
the abundance of tCtr1 (Fig. 1C). In contrast, MEFs treated with
the cysteine cathepsin/calpain protease inhibitor E64d dis-
played a striking reduction in the levels of tCtr1, suggesting that
one or more E64d-inhibitable proteases are involved in the pro-
teolytic processing of the Ctr1 ectodomain (Fig. 1D). A reduc-
tion in tCtr1 levels is also observed when Chinese hamster
ovary cells (CHO) or human embryonic kidney cells (HEK293T)
were treated with E64d, suggesting that Ctr1 truncation
occurs via a proteolytic mechanism that is conserved
among these species. The robust increase in tCtr1 levels caused
by induced expression of Ctr2 can be abrogated by incubation
with E64d (Fig. 1E). Together, these results suggest that the
generation of tCtr1 is a conserved proteolytic process mediated
by an E64d-inhibitable protease activity that acts downstream
of Ctr2.

Cathepsin Inhibition Decreases tCtr1 Levels and Increases
Copper Accumulation—The cell-permeable and irreversible
protease inhibitor E64d inhibits cysteine cathepsin proteases,
with a preference for cathepsins L and B at the doses used in our
experiments, as well as the calcium-dependent calpain prote-
ases (34). To explore which of these protease families is rele-
ant for the formation of tCtr1, proteases were evaluated for
co-localization with Ctr1 and Ctr2. Ctr1 has been shown to
continuously cycle between the plasma membrane and endo-
cytic vesicles, where it localizes to endolysosomal compart-
ments that also harbor Ctr2 (14, 30, 32, 35). Because Ctr1 clea-
amage has previously been suggested to occur at an endosomal
compartment (30), subcellular fractionation was carried out in
an attempt to localize Ctr1 with the appropriate protease. The
Ctr1 ectodomain faces the intraluminal space, and thus any
protease involved in Ctr1 cleavage must be present inside the
vesicular lumen. Because calpain proteases are localized to the
cytosol, our studies focused on cathepsins L and B as they are
known to primarily localize to endolysosomal compart-
ments. Analysis of subcellular fractions by immunoblotting revealed
that Ctr1, Ctr2, and cathepsins L and B co-fractionated
together with the lysosomal marker Lamp1 (Fig. 2A), indicating
that they are all in endolysosomal compartments.

To test the involvement of cathepsin L/B in generating tCtr1,
the extent of Ctr1 truncation was evaluated in WT MEFs and
those lacking cathepsin L or B. Cells lacking cathepsin L exhibit
low levels of tCtr1 and elevated levels of both the full-length and
a potential intermediate form of Ctr1 as compared with wild
type and cathepsin B-deficient cells (Fig. 2B). However, the
simultaneous absence of both cathepsins L and B caused a more severe reduction in Ctr1 ectodomain processing as compared with the absence of cathepsin L alone (Fig. 2C). The introduction of cathepsin L into cathepsin L−/−/B−/− cells rescued the Ctr1 processing activity. In agreement with these genetic validation experiments, WT MEFs treated with a cathepsin L-selective inhibitor (cathepsin L inhibitor III) were compromised for the generation of tCtr1, whereas cells treated with DMSO, 2 μg/ml TIMP-2, TIMP-3, and TAPI-2 or 5 μM BB-94 for 16 h, and protein extract was analyzed by immunoblotting with anti-Ctr1 (T, truncated; F, full-length) and anti-tubulin antibody. C, MEFs were treated with DMSO, 2 μg/ml TIMP-2, TIMP-3, and TAPI-2 or 5 μM BB-94 for 16 h, and protein extract was analyzed by immunoblotting with anti-Ctr1 (T, truncated; F, full-length) and anti-tubulin antibody. D, MEFs were treated with 10 μM E64d, and CHO and HEK cells were treated with 50 μM E64d for 16 h before immunoblot analysis as in B. E, Tet-On Ctr2 cells were cultured with or without 100 ng/ml doxycycline for 24 h before treatment with either DMSO or E64d (50 μM), and protein extracts were analyzed with immunoblotting as in B.

These results indicate that cathepsin L plays a prominent role in the processing of Ctr1 to form tCtr1 in MEFs, with a minor contribution by cathepsin B. Previous results demonstrated that MEFs or mouse tissues lacking Ctr2 have increased levels of full-length Ctr1, decreased tCtr1, and a corresponding increase in intracellular Cu⁺ levels (32). Hence, to assess whether the increase in intracellular Cu⁺ observed in Ctr2-deficient cells and tissues is imposed by inhibition of cathepsin-mediated Ctr1 processing, MEFs were incubated with E64d and cell-associated copper was measured. Indeed, MEFs treated with E64d exhibited elevated cell-associated copper levels (Fig. 2E), and MEFs treated with a cathepsin L-specific inhibitor showed a similar increase in copper accumulation (Fig. 2E). Taken together, these data demonstrate that inhibition or loss of cathepsin L reduces Ctr1 ectodomain cleavage, which results in more full-length Ctr1 and elevated copper accumulation. Moreover, these results identify cathepsins L and B as critical components for Ctr1 ectodomain processing that play an important role in Cu⁺ uptake in cultured cells.
Contribution of Cathepsin B and Ctr2 to the Processing of Ctr1—Data presented here demonstrate that the Ctr2 integral membrane protein stimulates Ctr1 ectodomain cleavage in a cysteine protease-dependent manner, and we have identified cathepsin L as having a major role in this process. To further decipher a potential role for cathepsin B, or other E64d-inhibitable proteases in the processing of Ctr1, WT and cathepsin L−/−/H11002−/−/H11002 MEFs were treated with E64d. Indeed, cathepsin L−/−/H11002−/−/H11002 MEFs treated with E64d showed higher levels of full-length Ctr1, suggesting that cathepsin B contributes to Ctr1 ectodomain processing (Fig. 3A). However, cathepsin L represents the majority of the proteolytic activity involved in biogenesis of tCtr1 in MEFs.

To gain insight into how Ctr2 regulates the processing of Ctr1 to tCtr1, in concert with cathepsins, Ctr2 expression was knocked down in both WT and cathepsin L−/−/H11002−/−/H11002 MEFs. As has been observed previously, silencing of Ctr2 in WT MEFs reduced the levels of tCtr1 and increased full-length Ctr1 (Fig. 3B). Notably, in cathepsin L−/−/H11002−/−/H11002 cells, where the steady state levels of tCtr1 levels are low, silencing of Ctr2 caused a further reduction in the levels of truncated Ctr1. This indicates that, although cathepsin L has a major role in Ctr1 processing, Ctr2 also stimulates formation of tCtr1 via means other than cathepsin L. This observation is supported by data in Fig. 2A showing that residual tCtr1 is observed in cells lacking cathepsin L.

Interestingly, cells lacking cathepsin L show increased levels of cathepsin B (Fig. 3C). This suggests that cathepsin B might also contribute to Ctr1 processing, a notion supported by the observed lower levels of tCtr1 in cathepsin L−/−/H11002−/−, cathepsin B−/−/H11002−/− double-deficient cells compared with cathepsin L−/−/H11002−/− cells (Fig. 2C). This observation is in agreement with a previous study showing that cathepsin B levels increase in mice and cells lacking cathepsin L and by genetic studies showing that cathepsins B and L functionally compensate each other (36, 37).

To assess whether Ctr2 regulates Ctr1 ectodomain cleavage by recruiting Ctr1 or cathepsin L to endolysosomes, subcellular fractionation was performed to compare the localization of these proteins in WT and Ctr2−/−/H11002−/−/H11002 MEFs. Immunoblot analysis...
revealed that Ctr1, Ctr2, and cathepsin L were all found in the same fraction, together with the lysosomal marker Lamp1, in both WT and Ctr2−/− cells (Fig. 3D). We noted that the levels of pro-cathepsin L were modestly increased in MEFs lacking Ctr2, suggesting that Ctr2 could promote cathepsin L processing of the Ctr1 ectodomain by mechanisms other than affecting its subcellular localization or expression. Taken together, these data suggest that Ctr1 ectodomain processing occurs in endolysosomal compartments containing both Ctr2 and the cysteine cathepsins, but Ctr2 is not necessary for their recruitment to this compartment.

Cathepsin L Cleaves the Ctr1 Ectodomain in Vitro and Primes Further Processing—Although cathepsin L functions in Ctr1 ectodomain cleavage and in the regulation of Cu+ uptake in MEFs, it is not known whether cathepsin L plays a direct or indirect role in this process. To address this question, an in vitro substrate processing assay was developed using recombinant cathepsin L and recombinant CTR1 ectodomains (Fig. 4A). Incubation of the purified CTR1 ectodomain with cathepsin L at a range of concentrations, followed by SDS-PAGE and Ponceau S staining revealed the formation of two lower molecular weight protein species in a cathepsin L dose-dependent manner (Fig. 4B). Mass spectrometry analysis identified the species as CTR1 ectodomain fragments generated as the result of cleavage between residues 8 and 9 from the amino terminus (Fig. 4C, indicated by red arrowhead) (see supplemental Fig. S1 for high resolution MS/MS spectrum (A) and deconvoluted MS spectrum (B)).

The cathepsin L-mediated Ctr1 ectodomain cleavage site is conserved among mammals (Fig. 4C) raising the possibility that Ctr1 cleavage by this enzyme may be a common feature among mammals. However, the amino terminus generated by cathepsin L cleavage in vitro is not synonymous with the amino terminus of the tCtr1 generated in vivo, previously identified to begin within the methionine-rich region of both the mouse and human Ctr1 proteins (32) (Fig. 4C, indicated by blue arrowheads). This suggests that post-cathepsin L processing of Ctr1 occurs to yield the fully processed tCtr1. To assess this possibility and to ascertain a potential role for Ctr2 in this mechanism, a Ctr1−/− Ctr2−/− MEF cell line was generated in which Ctr2 expression is induced by doxycycline. In the absence of Ctr2, the abundance of tCtr1 is low and is further diminished by incubation with E64d (Fig. 4D, compare lanes 2 and 3). In agreement with previous results, cells lacking Ctr2 show increased full-length Ctr1 levels and decreased tCtr1 levels (Fig. 4D, compare lanes 2 and 7), and treatment with E64d decreased tCtr1 levels (Fig. 4D, compare lane 2 versus lane 3 and lane 7 versus lane 8). Expression of a Ctr1 variant (Ctr1Δ1–8), to mimic the post-cathepsin L cleavage form, was further processed to yield a Ctr1 species that electrophoretically co-migrates with tCtr1 (Fig. 4D, lane 4). Interestingly, processing of the Ctr1Δ1–8 variant proceeded in the absence of Ctr2, although expression of
Ct2 further enhanced the production of tCtr1 (Fig. 4D, compare lanes 4 and 9). Although treatment with E64d gave rise to slightly higher levels of uncleaved Ctr1/H9004_1–8, tCtr1 was still present (Fig. 4D, compare lanes 4 and 5). Notably, the contribution of Ct2 to the processing of Ctr1/H9004_1–8 is abrogated by addition of E64d (Fig. 4D, compare lanes 4 and 5 to lanes 9 and 10), suggesting that the formation of tCtr1 is initiated by cathepsin L and proceeds via both E64d-sensitive and E64d-resistant proteases, with Ct2 stimulating the E64d-sensitive proteases. Taken together, these results suggest that proteases other than cathepsin L participate in Ct1 ectodomain processing, but they function downstream of the rate-limiting cathepsin L cleavage.

**Cathepsin L**/H11002/** Cathepsin L**/** Cathepsin L**/H11002 Mice Are Defective in Ctr1 Processing and Accumulate Copper—Data presented here demonstrate a direct and rate-limiting role for cathepsin L in Ct1 ectodomain cleavage and in the modulation of cellular copper accumulation. To investigate a potential physiological role for cathepsin L in Ct1 ectodomain cleavage and copper accumulation in animals, cathepsin L/** Cathepsin L**/** Cathepsin L**/H11002 mice were evaluated. Cathepsin L/** Cathepsin L**/** Cathepsin L**/H11002 mice exhibit increased copper accumulation in brain, lymph nodes, and testis in comparison with wild type littermates (Fig. 5A). However, cathepsin L deficiency did not affect copper levels in liver, a finding that is in agreement with the lack of impact of Ct2-deficiency on liver copper levels (32). Zinc levels were not different between wild type and cathepsin L/** Cathepsin L**/** Cathepsin L**/H11002 mice (Fig. 5B). Moreover, lower levels of tCtr1 were observed in lymph nodes and kidneys from cathepsin L/** Cathepsin L**/** Cathepsin L**/H11002 mice as compared with wild type mice, along with elevated levels of full-length Ctr1 in brain, spleen, lymph nodes, and testis (Fig. 5C). Indeed, the tissue types that exhibited increased copper accumulation and decreased Ctr1 cleavage in cathepsin L/** Cathepsin L**/** Cathepsin L**/H11002 mice paralleled the tissues demonstrating similar defects in Ct2/** Cathepsin L**/** Cathepsin L**/H11002 mice (32). The considerable amount of tCtr1 in cathepsin L/** Cathepsin L**/** Cathepsin L**/H11002 mouse tissues suggests a discrepancy between the Ctr1 processing in mice compared with MEFs. Hence, in the cathepsin L/** Cathepsin L**/** Cathepsin L**/H11002 mice, cathepsin L or B may be more dominant in some tissues, whereas in MEFs cathepsin L may be the primary protease responsible for Ctr1 ectodomain cleavage. Taken together, these observations support a physiological role for cathepsin L, working in concert with Ct2, in Ct1 ectodomain cleavage. Additionally, these studies establish cathepsin L as a novel physiological regulator of mammalian copper homeostasis.

**Cathepsin L Inhibition Enhances Cisplatin Accumulation and Cell Death**—Cisplatin and related derivatives are platinum-based chemotherapeutic agents widely used for cancer types, including ovarian, colon, lung, testicular, and head and neck (38). Previous studies demonstrated that mammalian Ctr1 functions in cisplatin uptake, that cisplatin binds directly to methionine residues within the Ctr1 ectodomain, and that the
Processing of Ctr1 Ectodomain

FIGURE 5. Cathepsin L−/− mice exhibit defects in Ctr1 ectodomain cleavage and accumulate copper. A, 2-month-old wild type (cathepsin L−/−) and cathepsin L+/− mice were analyzed for copper levels by ICP-MS in brain (Br), liver (Li), kidney (Ki), spleen (Sp), lymph nodes (Ly), and testis (Te). Note different scales for copper levels in different tissues. B, tissue zinc analysis as in A. Data are presented as means ± S.D. from three to four mice, *, p < 0.05; **, p < 0.01. C, protein extracts from the indicated tissues from WT (+/+) and cathepsin L−/− (Cath L−/−) littermates were immunoblotted with anti-Ctr1 and anti-SOD1 antibody, with cathepsin L genotypes indicated. Shown are the full-length (F) and truncated (T) forms of Ctr1. A short exposure shows the abundance of tCtr1 and a longer exposure reveals the expression of both full-length and truncated Ctr1.

Cath L−/− MEFs, which express more full-length Ctr1, accumulate significantly higher levels of cisplatin compared with WT MEFs (32). To test whether preservation of the Ctr1 cisplatin-binding ectodomain by inhibiting the rate-limiting step in cleavage augments cisplatin accumulation, Ctr1−/− MEFs were transfected with an empty vector or a vector expressing Ctr1 and treated with either vehicle or cathepsin L inhibitor, in combination with cisplatin. Ctr1−/− MEFs transfected with the Ctr1 expression plasmid accumulated more platinum as compared with vector-transfected cells (Fig. 6A). Moreover, when Ctr1-expressing cells were treated with the cathepsin L inhibitor, platinum accumulation strongly increased over untreated cells. These results demonstrate that cisplatin uptake is stimulated by co-administration of a cathepsin L inhibitor and, furthermore, that the stimulation of cisplatin accumulation is dependent on Ctr1. Given the results presented here, this likely occurs via inhibition of Ctr1 ectodomain cleavage mediated by cathepsin L. To investigate whether the increased cisplatin accumulation provoked by inhibition of cysteine cathepsins enhances cisplatin-mediated toxicity, cell viability was measured after addition of E64d, in combination with cisplatin, to WT and Ctr1−/− MEFs. Cisplatin treatment alone reduced cell viability by 28%, whereas a combination of cisplatin and E64d reduced cell viability further to 43% (Fig. 6B). MEFs lacking Ctr1 displayed no additional reduction in cell viability when cells were treated with E64d (Fig. 6B), demonstrating that the decreased cell survival following treatment with cisplatin in combination with E64d is dependent on Ctr1-mediated cisplatin uptake.

Discussion

The Ctr1 high-affinity copper transporter exists as two species, full-length and tCtr1, at varying levels in different cell lines and tissues (18, 31, 32). We previously demonstrated that MEFs and specific mouse tissues lacking the Ctr2 integral membrane protein have lower levels of tCtr1, increased levels of full-length Ctr1, and a corresponding increase in copper accumulation (32). Here, we demonstrate that tCtr1 is generated by proteolytic cleavage of full-length Ctr1, which is initiated by the cysteine cathepsins L and B, and that this cleavage occurs in a Ctr2-dependent manner. We also demonstrate that truncation of Ctr1 by these cathepsins has a functional impact on cellular accumulation of both Cu2+ and cisplatin, both of which bind directly to the metal ligand-rich ectodomain (24, 26, 27, 29). Our results establish cathepsin L/B cleavage as a direct and rate-limiting step in the generation of tCtr1. Moreover, these observations establish a new mechanism for the regulation of Ctr1-mediated Cu2+ accumulation and identify cathepsin L, and to a lesser extent cathepsin B, as an important regulator of the mammalian copper homeostasis machinery. In line with our findings, proteolytic ectodomain processing of Zip4 has been proposed to be a regulatory mechanisms controlling zinc uptake by Zip4 (41).

We previously demonstrated that Ctr1 and Ctr2 form a complex in vivo and co-purify in the same endolysosomal enrichment fraction (32). Cathepsins L and B are classical proteases of the endolysosome that also co-purify with the Ctr1- and Ctr2-containing vesicular fraction, potentially placing these components in proximity for their involvement in Ctr1 ectodomain cleavage. We envisage distinct mechanisms whereby Ctr2 and cathepsins L/B could function in concert to initiate Ctr1 ectodomain removal (Fig. 6C). Upon endocytosis from the plasma membrane into an endolysosomal compartment, Ctr1 could interact with Ctr2 in a manner that stimulates cleavage by cathepsin L/B. This could occur either by Ctr2-mediated recruitment of cathepsin L/B [1] or by a Ctr2-induced conformational change in the Ctr1 ectodomain such that the cleavage site for cathepsin L/B becomes accessible [2] (see Fig. 6C). Because Ctr1 undergoes constitutive endocytosis and recycling to the plasma membrane (14, 15, 35, 42), ectodomain cleavage within the endolysosomal compartment would result in population of the plasma membrane with tCtr1 molecules, thereby reducing Cu2+ import relative to a Ctr1-enriched plasma membrane. Interestingly, blocking the Ctr1 ectodomain O-linked
glycosylation by mutating Thr-27 increased the abundance of tCtr1 (31). Although Thr-27 is distal to the cathepsin L cleavage site within the ectodomain, glycosylation could sterically hinder cleavage at position 8 within the ectodomain. This raises the possibility that ectodomain cleavage, and therefore Cu\(^{+}\) transport, could also be regulated by cellular glycosylation/deglycosylation enzymes. As copper concentrations near or above the apparent \(K_m\) value stimulate Ctr1 endocytosis (15), it is possible that this trafficking event serves as a regulatory step to reduce Cu\(^{+}\) uptake via enhancing cleavage of the Ctr1 ectodomain, thereby locating a lower efficiency Cu\(^{+}\) transporter at the cell surface, without the wholesale removal of Ctr1 from the plasma membrane. Additional studies will be required to decipher whether and how Ctr1 cleavage is regulated as a function of cellular copper status. It is also intriguing that in both Ctr2\(^{-/-}\) and cathepsin L\(^{-/-}\) mice, the same tissue-specific patterns of diminished Ctr1 ectodomain cleavage and increased copper accumulation are apparent (32). This could be due to differences in the expression or activity of Ctr2, cathepsin L/B, or other as yet unknown components of this pathway to

FIGURE 6. Cathepsin L inhibition of Ctr1 ectodomain cleavage enhances cisplatin accumulation and efficacy in vitro. A, Ctr1\(^{-/-}\) MEFs were transfected with vector control (v) or vector containing human Ctr1 (hCtr1) and treated either with DMSO or 10 \(\mu\)M cathepsin L inhibitor for 16 h followed by a pulse of 200 \(\mu\)M cisplatin for 2 h. Cells were harvested and total cellular platinum (Pt) levels measured by ICP-MS and normalized to protein concentrations. B, wild type or Ctr1\(^{-/-}\) MEFs were pre-treated with DMSO or 10 \(\mu\)M E64d for 2 h followed by DMSO or 50 \(\mu\)M cisplatin for 12 h, and cell viability was assessed by recording the formation of the fluorescent product resorufin, with normalization against vehicle-treated cells. Data are presented as mean ± S.D. from three to four biological replicates. *, \(p \leq 0.05\); **, \(p \leq 0.01\); ***, \(p \leq 0.001\). C, model for the Ctr2 and cathepsin L (Cath L)-mediated cleavage of the Ctr1 ectodomain to generate tCtr1, within an endolysosomal compartment. In this model, we envision two mechanisms by which Ctr2 and cathepsin L/B cooperate in Ctr1 ectodomain cleavage; [1] binding of Ctr2 to Ctr1 may provoke a conformational switch in the Ctr1 ectodomain, providing access by cathepsin L/B, or [2] Ctr2 may recruit cathepsin L/B and deliver the protease to the ectodomain cleavage site.
Processing of Ctr1 Ectodomain

Ctr2/cathepsin-independent Ctr1 ectodomain cleavage mechanisms or to differences in Ctr1 trafficking, as has been observed in distinct mouse tissues (43–45).

The cysteine cathepsins have historically been thought of as quite nonspecific proteases involved in bulk degradation of lysosomal content (46, 47). However, recent evidence has shown that several cathepsins have specific biological functions by cleaving substrates at specific sites, thereby acting as convertases to modulate the production or activity of peptide hormones, histones, complement factors, proteases, vesicular transporters, and even as sheddases by cleaving ectodomains of several membrane-anchored adhesion proteins and receptors (48–58). Cathepsin L cleavage specificity is primarily guided by P2 preference for aromatic, and to lesser extent aliphatic, amino acids downstream of the cleavage site (42, 59, 60). The cleavage site in Ctr1 identified by mass spectrometry revealed that there is a conserved Met at the P2 site in Ctr1, offering a good substrate-protected site. Interestingly, the cathepsin L cleavage site within the Ctr1 ectodomain is conserved across a variety of mammalian genomes that also encode a Ctr2 homologue. Given the difference between the location of the cathepsin L cleavage site in vitro, compared with the amino terminus of tCtr1 in vivo (32), it is possible that Ctr2 or other factors could influence the cathepsin L cleavage site choice in vivo.

Ctr1 plays a significant role in cisplatin import in mammalian cells (25, 28, 61). Similar to Cu⁺, platinum binds to Met-rich motifs within the Ctr1 ectodomain (27), but studies using Ctr1 mutants that are defective in Cu⁺ transport, but competent for cisplatin acquisition, suggest that Ctr1 delivers platinum into cells via receptor-mediated endocytosis rather than acting as a membrane channel as it does for Cu⁺ (15, 26). Cancer patient survival after treatment with platinum-based drugs is associated with high levels of CTR1 expression and lower CTR1 levels associated with decreased survival to cisplatin (62, 63). Intriguingly, and in contrast to CTR1, low levels of CTR2 positively associate with patient survival after cisplatin therapy (63, 64). In agreement with this observation, cultured cells lacking Ctr2 exhibit increased whole-cell platinum accumulation (32, 65). Also, low Ctr2 levels correlate with an increased sensitivity to platinum treatment in several cancer cell lines (66). Low Ctr2 levels would be expected to give rise to increased Ctr1 harboring the platinum-binding ectodomain, thereby increasing uptake. Interestingly, high cathepsin B and L expression levels have been associated with poor prognosis for multiple cancer entities, although knock-out or inhibition of cathepsins attenuates cancer progression and enhances the efficacy of chemotherapy (67, 68). Taken together, these results support a concept in which cathepsin L/B together with Ctr2 modulate both Cu⁺ and platinum accumulation via a Ctr1-dependent mechanism involving Ctr1 ectodomain cleavage. The discovery that cathepsin L/B function in the modulation of Ctr1-dependent Cu⁺ transport identifies these proteases as new components of the copper homeostasis machinery and potentially provides a new point for the regulation of copper transport. Perhaps the pharmacological modulation of this pathway could enhance cisplatin efficacy in resistant tumors or decrease the therapeutic dose needed for clinical efficacy.

Acknowledgments—We thank Drs. R. Festa and S. Garcia-Santamarina and Professor G. Pejler for valuable comments on this manuscript. We also thank U. Reif, S. Dollwet-Mack, M. Vizovisek, and I. Stefe for excellent technical assistance.

References

1. Kim, B. O., Nevitt, T., and Thiele, D. J. (2008) Mechanisms for copper acquisition, distribution and regulation. Nat. Chem. Biol. 4, 176–185
2. Nevitt, T., Ohrvik, H., and Thiele, D. J. (2012) Charting the travels of copper in eukaryotes from yeast to mammals. Biochim. Biophys. Acta 1823, 1580–1593
3. Madsen, E., and Gitlin, J. D. (2007) Copper and iron disorders of the brain. Annu. Rev. Neurosci. 30, 317–337
4. Medeiros, D. M., Davidson, J., and Jenkins, J. E. (1993) A unified perspective on copper deficiency and cardiomyopathy. Proc. Soc. Exp. Biol. Med. 203, 262–273
5. Collins, J. F., Prohaska, J. R., and Knutson, M. D. (2010) Metabolic crossroads of iron and copper. Nutr. Rev. 68, 133–147
6. Lukaszewycz, O. A., and Prohaska, J. R. (1990) The immune response in copper deficiency. Ann. N.Y. Acad. Sci. 587, 147–159
7. Dancis, A., Yuan, D. S., Haile, D., Askwith, C., Eide, D., Moehle, C., Kaplan, J., and Klausner, R. D. (1994) Molecular characterization of a copper transport protein in S. cerevisiae: an unexpected role for copper in iron transport. Cell 76, 393–402
8. Pena, M. M., Puig, S., and Thiele, D. J. (2000) Characterization of the Saccharomyces cerevisiae high affinity copper transporter Ctr3. J. Biol. Chem. 275, 33244–33251
9. Turski, M. L., and Thiele, D. J. (2007) Drosophila Ctr1A functions as a copper transporter essential for development. J. Biol. Chem. 282, 24017–24026
10. Sancenón, V., Puig, S., Mira, H., Thiele, D. J., and Peñarrubia, L. (2003) Identification of a copper transporter family in Arabidopsis thaliana. Plant Mol. Biol. 51, 577–587
11. Riggio, M., Lee, J., Scudiero, R., Parisi, E., Thiele, D. J., and Filosa, S. (2002) High affinity copper transporter protein in the lizard Podarcis sicula: molecular cloning, functional characterization and expression in somatic tissues, follicular oocytes and eggs. Biochim. Biophys. Acta 1576, 127–135
12. Lee, J., Prohaska, J. R., and Thiele, D. J. (2001) Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc. Natl. Acad. Sci. U.S.A. 98, 6842–6847
13. Kuo, Y. M., Zhou, B., Cosco, D., and Gitschier, J. (2001) The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc. Natl. Acad. Sci. U.S.A. 98, 6836–6841
14. Petris, M. J., Smith, K., Lee, J., and Thiele, D. J. (2003) Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J. Biol. Chem. 278, 9639–9646
15. Guo, Y., Smith, K., Lee, J., Thiele, D. J., and Petris, M. J. (2004) Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter. J. Biol. Chem. 279, 17428–17433
16. Klomp, A. E., Tops, B. B., Van Denberg, I. E., Berger, R., and Klomp, L. W. (2010) Biochemical characterization and subcellular localization of human copper transporter 1 (hCtr1). Biochem. J. 364, 497–505
17. Eisses, J. F., Chi, Y., and Kaplan, J. H. (2005) Stable plasma membrane levels of hCTR1 mediate cellular copper uptake. J. Biol. Chem. 280, 9635–9639
18. Nose, Y., Wood, L. K., Kim, B. E., Prohaska, J. R., Fry, R. S., Spears, J. W.,
The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. \textit{Mol. Pharmacol.} 78, 333–339

Kuo, M. T., Fu, S., Savaraj, N., and Chen, H. H. (2012) Role of the human high affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. \textit{Cancer Res.} 72, 4616–4621

Kambe, T., and Andrews, G. K. (2009) Novel proteolytic processing of the ectodomain of the zinc transporter ZIP4 (SLC39A4) during zinc deficiency is inhibited by acrodermatitis enteropathica mutations. \textit{Mol. Cell. Biol.} 29, 129–139

Towatari, T., and Katunuma, N. (1983) Selective cleavage of peptide bonds by cathepsins L and B from rat liver. \textit{J. Biol. Chem.} 93, 1119–1128

Hardman, B., Manuelpillai, U., Wallace, E. M., Monty, J. F., Kramer, D. R., Kuo, Y. M., Mercer, J. F., and Ackland, M. L. (2006) Expression, localisation and hormone regulation of the human copper transporter hCTR1 in placenta and chorionicarcinoma Jeg-3 cells. \textit{Placenta} 27, 968–977

Kuo, Y. M., Gybina, A. A., Pyatkovit, J. W., Gitschier, J., and Prohaska, J. R. (2006) Copper transport protein (Ctri) levels in mice are tissue specific and dependent on copper status. \textit{J. Nutr.} 136, 21–26

Ralle, M., Huster, D., Vogt, S., Schirrmieier, W., Burkhead, J. L., Capps, T. R., Gray, L. L., Bly, M., Maryon, E., and Lusenko, S. (2010) Wilson disease at a single cell level: intracellular copper trafficking activates compartment-specific responses in hepatocytes. \textit{J. Biol. Chem.} 285, 30875–30883

Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B., and Turk, D. (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. \textit{Biochim. Biophys. Acta} 1824, 68–88

Vasiljeva, O., Reineckeckl, T., Peters, C., Turk, D., Turk, V., and Turk, B. (2007) Emerging roles of cysteine cathepsins in disease and their potential as drug targets. \textit{Curr. Pharm. Des.} 13, 387–403

Reddy, V. B., Sun, S., Azimi, E., Elmariah, S. B., Dong, X., and Lerner, E. A. (2015) Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of Mrgprs. \textit{Nat. Commun.} 6, 7864

Garcia-Cattaneo, A., Cobert, F. X., Mecer, M., Toscano, F., Flores, M., Lescure, A. D., Del Nery, E., and Benachor, P. (2012) Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. \textit{Proc. Natl. Acad. Sci. U.S.A.} 109, 9053–9058

Funkelstein, L., Tonelli, R., Mosier, C., Hwang, S. R., Beuschlein, F., Lichttenauer, U. D., Reineckeckl, T., Peters, C., and Hook, V. (2008) Major role of cathepsin L for producing the peptide hormones ACTH, β-endorphin, and α-MSH, illustrated by protease gene knockout and expression. \textit{J. Biol. Chem.} 283, 35652–35659

Duncan, E. M., Muraturo-Scrander, T. L., Cook, R. G., Garcia, B. A., Shabanovitz, J., Hunt, D. F., and Allis, C. D. (2008) Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. \textit{Cell} 135, 284–294

Liszewski, M. K., Kolev, M., Le Fric, G., Leung, M., Bertram, P. G. F., Fara, A. S., Subias, M., Pickering, M. C., Drouet, C., Merci, S., Aristila, T. P., Pekkarinen, P. T., Ma, M., Cope, A., Reineckeckl, T., et al. (2013) Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. \textit{Immunity} 39, 1143–1157

Nakagawa, T., Roth, W., Wong, P., Nelson, A., Farr, A., Deussing, J., Villadangos, J. A., Ploegh, H., Peters, C., and Rudensky, A. Y. (1998) Cathepsin L critical role in II degradation and CD4 T cell selection in the thymus. \textit{Science} 280, 450–453

Savals, L. R., Gassier, B., Damme, M., Lübke, T., Wrocklage, C., Debacker, C., Jęgowa, A., Reineckeckl, T., Hasilik, A., Sañig, P., and Schröder, B. (2011) Disrupted in renal carcinoma 2 (DIR2C2), a novel transporter of the lysosomal membrane, is proteolytically processed by cathepsin L. \textit{Biochim. J.} 439, 113–128

Steunnen, P., Froemming, J., Reineckeckl, T., and Storch, S. (2012) Proteolytic cleavage of the disease-related lysosomal membrane glycoprotein CLN7. \textit{Biochim. Biophys. Acta} 1822, 1617–1628

Soboti, B., Vizovišek, M., Vidmar, R., Van Damme, P., Gocheva, V., Joyce, J. A., Veber, K., Turk, V., Turk, B., and Fonovic, M. (2015) Proteomic identification of cysteine cathepsin substrates shed from the surface of cancer cells. \textit{Mol. Cell. Proteomics} 14, 2213–2228

Müller, S., Dennemärker, J., and Reineckeckl, T. (2012) Specific functions
of lysosomal proteases in endocytic and autophagic pathways. Biochim. Biophys. Acta 1824, 34–43
58. Yasothornsrikul, S., Greenbaum, D., Medzhiradszky, K. F., Toneff, T., Bundey, R., Miller, R., Schilling, B., Petermann, I., Dehnert, J., Logvinova, A., Goldsmith, P., Neveu, J. M., Lane, W. S., Gibson, B., Reinheckel, T., et al. (2003) Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc. Natl. Acad. Sci. U.S.A. 100, 9590–9595
59. Vizovišek, M., Vidmar, R., Van Quickelberghe, E., Impens, F., Andjelković, U., Sobotic, B., Stoka, V., Gevaert, K., Turk, B., and Fonović, M. (2015) Fast profiling of protease specificity reveals similar substrate specificities for cathepsins K, L, and S. Proteomics 15, 2479–2490
60. Puzer, L., Cotrin, S. S., Alves, M. F., Egborge, T., Araújo, M. S., Juliano, M. A., Juliano, L., Brömme, D., and Carmona, A. K. (2004) Comparative substrate specificity analysis of recombinant human cathepsin V and cathepsin L. Arch. Biochem. Biophys. 430, 274–283
61. Song, I. S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., and Kuo, M. T. (2004) Role of human copper transporter Ctrl in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol. Cancer Ther. 3, 1543–1549
62. Xu, X., Ren, H., Zhou, B., Zhao, Y., Yuan, R., Ma, R., Zhou, H., and Liu, Z. (2012) Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer 77, 438–442
63. Lee, Y. Y., Choi, C. H., Do, I. G., Song, S. Y., Lee, W., Park, H. S., Song, T. J., Kim, M. K., Kim, T. J., Lee, J. W., Bae, D. S., and Kim, B. G. (2011) Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol 122, 361–365
64. Yoshida, H., Teramae, M., Yamauchi, M., Fukuda, T., Yasui, T., Sumi, T., Honda, K., and Ishiko, O. (2013) Association of copper transporter expression with platinum resistance in epithelial ovarian cancer. Anticancer Res. 33, 1409–1414
65. Blair, B. G., Larson, C. A., Adams, P. L., Abada, P. B., Safaei, R., and Howell, S. B. (2010) Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 77, 912–921
66. Blair, B. G., Larson, C. A., Safaei, R., and Howell, S. B. (2009) Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin. Cancer Res. 15, 4312–4321
67. Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., and Joyce, J. A. (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25, 2465–2479
68. Olson, O. C., and Joyce, J. A. (2015) Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer 15, 712–729